Surgical optimization and characterization of a minimally invasive aortic banding procedure to induce cardiac hypertrophy in mice

Experimental Physiology

Volumn 97, Issue 7, 2012, Pages 822-832

  Martin, Tamara P ^a   Robinson, Emma ^b   Harvey, Adam P ^b   Macdonald, Margaret ^a   Grieve, David J ^b   Paul, Andrew ^a   Currie, Susan ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLURANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR INFLAMMATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; FEMALE; HEART CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE; MALE; MINIMALLY INVASIVE CARDIAC SURGERY; MINIMALLY INVASIVE TRANSVERSE AORTIC BANDING; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE;

EID: 84863826835     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.065573     Document Type: Article

References (34)

1. Alter P, Rupp H & Maisch B (2006). Activated nuclear transcription factor κB in patients with myocarditis and dilated cardiomyopathy-relation to inflammation and cardiac function. Biochem Biophys Res Commun 339, 180-187.
2. Arras M, Autenried P, Rettich A, Spaeni D & Rülicke T (2001). Optimization of intraperitoneal injection anaesthesia in mice: drugs, dosages, adverse effects and anaesthesia depth. Comp Med 51, 443-456.
3. Bayes-Genis A (2007). Hypertrophy and inflammation: too much for one heart. Eur Heart J 28, 661-663.
4. Buitrago S, Martin TE, Tetens-Woodring J, Belicha-Villanueva A & Wilding GE (2008). Safety and efficacy of various combinations of injectable anaesthetics in BALB/c mice. J Am Assoc Lab Anim Sci 47, 11-17.
5. Burlew BS & Weber KT (2002). Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27, 92-98.
6. Diez J, Lopez B, Gonzalez A & Querejeta R (2007). The role of myocardial collagen network in hypertensive heart disease. Curr Hyperten Rev 3, 1-7.
7. Flecknell P (1996). Laboratory Animal Anaesthesia, second edn. Academic Press, London.
8. Gupta S, Purcell NH, Lin A & Sen S (2002). Activation of nuclear factor κB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159, 1019-1028.
9. Hedayat M, Mahmoudi MJ, Rose NR & Rezaei N (2010). Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15, 543-562.
10. Ho C, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J & Seidman CE (2010). Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363, 552-563.
11. Hu P, Zhang D, Swenson L, Chakrabati G, Abel ED & Litwin SE (2003). Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signalling during pressure overload. Am J Physiol Heart Circ Physiol 285, H1261-H1269.
12. Izumo S, Lompré AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B & Mahdavi V (1987). Myosin heavy chain mRNA and protein isoform transitions during cardiac hypertrophy. Interaction between haemodynamic and thyroid hormone-induced signals. J Clin Invest 79, 970-977.
13. Junqueira LCU, Bignolas G & Brentani RR (1979). Picosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 11, 447-455.
14. Kashiwase K, Higuchi Y, Hirotani S, Yamaguchi O, Hikoso S, Takeda T, Watanabe T, Taniike M, Nakai A, Tsujimoto I, Matsumura Y, Ueno H, Nishida K, Hori M & Otsu K (2005). CaMKII activates ASK1 and NF-κB to induce cardiomyocyte hypertrophy. Biochem Biophys Res Commun 327, 136-142.
15. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Matsumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S & Ikeda U (2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594-604.
16. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL & Li C (2004). NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol 287, H1712-H1720.
17. Liu SF, Ye X & Malik AB (1997). In vivo inhibition of nuclear factor-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 159, 3976-3983.
18. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Thiem NV & Swynghedauw B (1979). Myosin isoenzyme redistribution in chronic heart overload. Nature 282, 105-107.
19. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ & Shah AM (2008). Involvement of Nox2 NADPH oxidase in adverse cardiac remodelling after myocardial infarction. Hypertension 51, 319-325.
20. Malave HA, Taylor AA, Nattama J, Deswal A & Mann DL (2003). Circulating levels of tumour necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild to moderate heart failure. Chest 123, 716-724.
21. Mercadier JJ (2000). Progression from cardiac hypertrophy to heart failure. In Congestive Heart Failure, second edn, ed. Hosenpud - & Greenberg -, Lippincott Williams & Wilkins, Philadelphia.
22. Mercadier JJ, Lompré AM, Wisnewsky C, Samuel JL, Bercovici J, Swynghedauw B & Schwartz K (1981). Myosin isoenzmic changes in several models of rat cardiac hypertrophy. Circ Res 49, 525-532.
23. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F & Raman SV (2009). Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging 2, 437-443.
24. Nelson DR, Lauwers GY, Lau JY, Davis GL (2000) IL10 treatment reduces fibrosis in patients with chronic hepatitis C. Gastroenetrology 118, 655-660
25. q signalling cascade. Am J Physiol Heart Circ Physiol 295, H245-H255
26. Olson ER, Shamhart PE, Naugle JE & Meszaros JG (2008). Angiotensin II-induced extracellular signal regulated kinase 1/2 activation is mediated by protein kinase Cδ and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 51, 704-711.
27. Pye MP, Black M & Cobbe SM (1996). Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 31, 873-881.
28. Singh MV & Anderson ME (2011). Is CaMKII a link between inflammation and hypertrophy in heart? J Mol Med 89, 537-543.
29. Smeets PJH, Teunissen BEJ, Planavila A, Van den Bosch H, Willemsen PHM, Van der Vusse GJ & van Bilsen M (2008). Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPARδ. J Biol Chem 283, 29109-29118.
30. Stewart JA, Massey EP, Fix C, Zhu J, Goldsmith EC & Carver W (2010). Temporal alterations in cardiac fibroblast function following induction of pressure overload. Cell Tissue Res 340, 117-126.
31. Toischer K, Rokita AG, Unsöld B, Zhu W, Kararigas G, Sossalla S et al. (2010). Differential cardiac remodelling in preload versus afterload. Circulation 122, 993-1003.
32. Vasquez C, Benamer N & Morley GE (2011). The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased hearts. J Cardiovasc Pharmacol 57, 380-388.
33. Vasquez C, Mohandas P, Louie KL, Benamer N, Bapat AC & Morley GE (2010). Enhanced fibroblast-myocyte interactions in response to cardiac injury. Circ Res 107, 1011-1020.
34. Zhou Y, Foster S, Nieman BJ, Davidson L, Chen XJ & Henkelman RM (2004). Comprehensive transthoracic cardiac imaging in mice using ultrasound biomicroscopy with anatomical confirmation by magnetic resonance imaging. Physiol Genomics 18, 232-244.